Cholesterol gene therapy VERVE-102: NEJM data, LDL reduction by 62% https://ymaho.com/cholesterol-gene-therapy-verve-102-nejm-data-ldl-reduction-by-62
NEJM published phase 1b results of gene therapy VERVE-102: LDL reduction by 62% after a single injection. Analysis of efficacy, risks, and prospects for patients with hypercholesterolemia. Read more.
Bank of England's Largest Liquidity Test of Pension Funds https://ymaho.com/bank-of-england-s-largest-liquidity-test-of-pension-funds
Bank of England requires LDI funds to double liquidity reserves by September 2026. What are the risks of corporate bond sell-off and currency volatility? Analysis.
CRISPR in vivo reduces cholesterol by 60% in VERVE-102 study https://ymaho.com/crispr-in-vivo-reduces-cholesterol-by-60-in-verve-102-study
Single infusion of VERVE-201 sustainably lowers LDL by more than 60%. Learn how CRISPR editing is changing the hypercholesterolemia therapy market. Read the analysis.
VERVE-102 gene editing reduces cholesterol by 62% — analysis https://ymaho.com/verve-102-gene-editing-reduces-cholesterol-by-62-analysis
Phase 1 results of VERVE-102: sustained LDL-C reduction up to 62% in patients with hypercholesterolemia. Analysis of market implications and forecasts. Read more.
AAV gene therapy for HoFH: cholesterol reduction by 97.5% in clinical trial https://ymaho.com/aav-gene-therapy-for-hofh-cholesterol-reduction-by-97-5-in-clinical-trial
New AAV8 gene therapy NGGT006 for homozygous familial hypercholesterolemia reduced LDL-C by 97.5% in 3 weeks. Effect persists for 52 weeks. Find out who is eligible for treatment.
CRISPR gene editing: treatment of hypertriglyceridemia CTX310 https://ymaho.com/crispr-gene-editing-treatment-of-hypertriglyceridemia-ctx310
CRISPR Therapeutics presented CTX310 — a one-time gene therapy that reduces triglycerides by 82% and LDL by 86%. Learn about the revolution in dyslipidemia treatment and market prospects.
CRISPR therapy VERVE-102 reduces cholesterol by 62% after injection https://ymaho.com/crispr-therapy-verve-102-reduces-cholesterol-by-62-after-injection
Journal NEJM published data on the drug VERVE-102: a single CRISPR injection (base editing) reduces LDL by 62% for 18 months without serious side effects. Learn details about the revolutionary therapy.